Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of JP-1366 tablets versus Nexium in subjects with reflux esophagitis
CTR20243824Phase 3Completed
- Sponsor
- Livzon Pharmaceutical Group Inc.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zastaprazan in erosive esophagitis (EE), gastroesophageal reflux disease (GERD), sponsored by Livzon Pharmaceutical Group Inc.. Started Nov 2024; status: completed.
02
Drugs
zastaprazan
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on CTR20243824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243824.